Dr. Alissa M. Martin
Claim this profileChildren's Hospital of Michigan
Studies Tumors
Studies Cancer
8 reported clinical trials
34 drugs studied
Area of expertise
1Tumors
SMARCB1 positive
SMARCB1 negative
Stage II
2Cancer
SMARCB1 positive
SMARCB1 negative
Stage II
Affiliated Hospitals
Clinical Trials Alissa M. Martin is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria
More about Alissa M. Martin
Clinical Trial Related4 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Alissa M. Martin has experience with
- Cyclophosphamide
- Cytology Specimen Collection Procedure
- Vincristine
- Doxorubicin Hydrochloride
- Methotrexate
- Prednisolone
Breakdown of trials Alissa M. Martin has run
Tumors
Cancer
Congenital Mesoblastic Nephroma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alissa M. Martin specialize in?
Alissa M. Martin focuses on Tumors and Cancer. In particular, much of their work with Tumors has involved SMARCB1 positive patients, or patients who are SMARCB1 negative.
Is Alissa M. Martin currently recruiting for clinical trials?
Yes, Alissa M. Martin is currently recruiting for 4 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Alissa M. Martin has studied deeply?
Yes, Alissa M. Martin has studied treatments such as Cyclophosphamide, Cytology Specimen Collection Procedure, Vincristine.
What is the best way to schedule an appointment with Alissa M. Martin?
Apply for one of the trials that Alissa M. Martin is conducting.
What is the office address of Alissa M. Martin?
The office of Alissa M. Martin is located at: Children's Hospital of Michigan, Detroit, Michigan 48201 United States. This is the address for their practice at the Children's Hospital of Michigan.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.